摘要
炎症性肠病(inflammatory bowel disease, IBD)的发生与环境因素、宿主免疫状态、遗传易感性和菌群失调有关。测序技术的发展使得肠道菌群与IBD的关系得到了更深入的研究和多方面的证实。本文阐述IBD患者中菌群改变的特征及菌群失调在IBD发生发展中的作用及机制, 并讨论以菌群为基础的防控策略研发现状。以期为IBD预防、诊断、治疗及预后评估提供基于肠道菌群的生物标志物。
The occurrence of inflammatory bowel disease(IBD)is related to environmental factors,host immune status,genetic susceptibility and flora imbalance.With the development of sequencing technologies,the relationship between intestinal microbiota and IBD has been further studied and confirmed in many aspects.This article summarizes the characteristics of microbiota alterations in patients with IBD,as well as the role and mechanisms of microbiota dysbiosis in the onset and development of IBD,and discusses the research status of therapies based on intestinal microbiota,prospecting the future of intestinal flora in the prevention,diagnosis,treatment and prognosis of IBD.
作者
杨紫瑜
李敏
Yang Ziyu;Li Min(Department of Laboratory Medicine,Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200127,China)
出处
《中华预防医学杂志》
CAS
CSCD
北大核心
2022年第9期1175-1181,共7页
Chinese Journal of Preventive Medicine
基金
上海申康三年行动计划项目(SHDC2020CR3006A)
上海市科学技术委员会科研计划项目(19JC1413005)。
关键词
炎症性肠病
肠道菌群
菌群失调
防控
生物标志物
Inflammatory bowel disease
Gastrointestinal microbiome
Dysbiosis
Prevention and control
Biomarkers
作者简介
通信作者:李敏,Email:ruth_limin@126.com。
